245 related articles for article (PubMed ID: 18187530)
1. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
de Haas SL; de Visser SJ; van der Post JP; Schoemaker RC; van Dyck K; Murphy MG; de Smet M; Vessey LK; Ramakrishnan R; Xue L; Cohen AF; van Gerven JM
J Psychopharmacol; 2008 Jan; 22(1):24-32. PubMed ID: 18187530
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
de Haas SL; de Visser SJ; van der Post JP; de Smet M; Schoemaker RC; Rijnbeek B; Cohen AF; Vega JM; Agrawal NG; Goel TV; Simpson RC; Pearson LK; Li S; Hesney M; Murphy MG; van Gerven JM
J Psychopharmacol; 2007 Jun; 21(4):374-83. PubMed ID: 17092968
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.
Bailey JE; Papadopoulos A; Seddon K; Nutt DJ
J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427
[TBL] [Abstract][Full Text] [Related]
5. The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.
de Haas SL; Zoethout RW; Van Dyck K; De Smet M; Rosen LB; Murphy MG; Gottesdiener KM; Schoemaker RC; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Feb; 26(2):282-91. PubMed ID: 21890585
[TBL] [Abstract][Full Text] [Related]
6. AZD6280, a novel partial γ-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.
Chen X; Jacobs G; de Kam ML; Jaeger J; Lappalainen J; Maruff P; Smith MA; Cross AJ; Cohen A; van Gerven J
J Clin Psychopharmacol; 2015 Feb; 35(1):22-33. PubMed ID: 25493397
[TBL] [Abstract][Full Text] [Related]
7. NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy.
Mirza NR; Larsen JS; Mathiasen C; Jacobsen TA; Munro G; Erichsen HK; Nielsen AN; Troelsen KB; Nielsen EØ; Ahring PK
J Pharmacol Exp Ther; 2008 Dec; 327(3):954-68. PubMed ID: 18791063
[TBL] [Abstract][Full Text] [Related]
8. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
Carling RW; Madin A; Guiblin A; Russell MG; Moore KW; Mitchinson A; Sohal B; Pike A; Cook SM; Ragan IC; McKernan RM; Quirk K; Ferris P; Marshall G; Thompson SA; Wafford KA; Dawson GR; Atack JR; Harrison T; Castro JL; Street LJ
J Med Chem; 2005 Nov; 48(23):7089-92. PubMed ID: 16279764
[TBL] [Abstract][Full Text] [Related]
9. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
[TBL] [Abstract][Full Text] [Related]
10. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.
Atack JR; Wafford KA; Tye SJ; Cook SM; Sohal B; Pike A; Sur C; Melillo D; Bristow L; Bromidge F; Ragan I; Kerby J; Street L; Carling R; Castro JL; Whiting P; Dawson GR; McKernan RM
J Pharmacol Exp Ther; 2006 Jan; 316(1):410-22. PubMed ID: 16183706
[TBL] [Abstract][Full Text] [Related]
11. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.
Atack JR
CNS Neurosci Ther; 2008; 14(1):25-35. PubMed ID: 18482097
[TBL] [Abstract][Full Text] [Related]
12. GABA A receptor subtype selectivity underlying selective anxiolytic effect of baicalin.
Wang F; Xu Z; Ren L; Tsang SY; Xue H
Neuropharmacology; 2008 Dec; 55(7):1231-7. PubMed ID: 18723037
[TBL] [Abstract][Full Text] [Related]
13. Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers.
Satzger W; Engel RR; Ferguson E; Kapfhammer H; Eich FX; Hippius H
Pharmacopsychiatry; 1990 May; 23 Suppl 3():114-9. PubMed ID: 1974070
[TBL] [Abstract][Full Text] [Related]
14. A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Lewis RT; Blackaby WP; Blackburn T; Jennings AS; Pike A; Wilson RA; Hallett DJ; Cook SM; Ferris P; Marshall GR; Reynolds DS; Sheppard WF; Smith AJ; Sohal B; Stanley J; Tye SJ; Wafford KA; Atack JR
J Med Chem; 2006 Apr; 49(8):2600-10. PubMed ID: 16610803
[TBL] [Abstract][Full Text] [Related]
15. Segregating two inhibitory circuits in human motor cortex at the level of GABAA receptor subtypes: a TMS study.
Di Lazzaro V; Pilato F; Dileone M; Profice P; Ranieri F; Ricci V; Bria P; Tonali PA; Ziemann U
Clin Neurophysiol; 2007 Oct; 118(10):2207-14. PubMed ID: 17709293
[TBL] [Abstract][Full Text] [Related]
16. The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.
Chen X; Jacobs G; de Kam M; Jaeger J; Lappalainen J; Maruff P; Smith MA; Cross AJ; Cohen A; van Gerven J
Br J Clin Pharmacol; 2014 Dec; 78(6):1298-314. PubMed ID: 24802722
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam.
Brignell CM; Rosenthal J; Curran HV
J Psychopharmacol; 2007 Sep; 21(7):673-83. PubMed ID: 17606475
[TBL] [Abstract][Full Text] [Related]
18. 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1.
Carling RW; Moore KW; Street LJ; Wild D; Isted C; Leeson PD; Thomas S; O'Connor D; McKernan RM; Quirk K; Cook SM; Atack JR; Wafford KA; Thompson SA; Dawson GR; Ferris P; Castro JL
J Med Chem; 2004 Mar; 47(7):1807-22. PubMed ID: 15027873
[TBL] [Abstract][Full Text] [Related]
19. Effects of lorazepam and oxazepam on perceptual and procedural memory functions.
Martin J; Matthews A; Martin F; Kirkby KC; Alexander J; Daniels B
Psychopharmacology (Berl); 2002 Nov; 164(3):262-7. PubMed ID: 12424549
[TBL] [Abstract][Full Text] [Related]
20. NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects.
Zuiker RG; Chen X; Østerberg O; Mirza NR; Muglia P; de Kam M; Klaassen ES; van Gerven JM
J Psychopharmacol; 2016 Mar; 30(3):253-62. PubMed ID: 26655084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
